Table 5.
Baseline and demographic characteristics, clinical features, and outcome of patients with 3GCR-bacteremia compared with non-3GCR-bacteremia and MDR-bacteremia compared with non-MDR-bacteremia.
| Characteristic | 3GCR-Bacteremia [n = 22(%)] | Non-3GCR-Bacteremia [n = 53(%)] | P-value | MDR Bacteremia [n = 7(%)] | Non-MDR Bacteremia [n = 68(%)] | P-value |
|---|---|---|---|---|---|---|
| AGE (YEARS) | ||||||
| 0–18 | 1 (4.5) | 4 (7.5) | 0 (0) | 5 (7.4) | ||
| 18–65 | 19 (86.4) | 43 (81.1) | 6 (85.7) | 56 (82.4) | ||
| >65 | 2 (9.1) | 6 (11.3) | 0.846 | 1 (14.3) | 7 (10.3) | 0.734 |
| GENDER | ||||||
| Male | 9 (40.9) | 27 (50.9) | 3 (42.9) | 33 (48.5) | ||
| Female | 13 (59.1) | 26 (49.1) | 0.428 | 4 (57.1) | 35 (51.5) | 0.775 |
| TUMOR TYPE | ||||||
| Leukemia | 17 (77.3) | 39 (73.6) | 6 (85.7) | 50 (73.5) | ||
| Lymphoma | 4 (18.2) | 11 (20.8) | 0 (0) | 15 (22.1) | ||
| Solid | 1 (4.5) | 3 (5.7) | 0.944 | 1 (14.3) | 3 (4.4) | 0.243 |
| MASCC SCORE | ||||||
| >21 | 0 (0) | 5 (9.4) | 0 (0) | 5 (7.4) | ||
| <21 | 22 (100) | 48 (90.6) | 0.136 | 7 (100) | 63 (92.6) | 0.458 |
| NEUTROPENIA DURATION PRIOR TO BACTEREMIA | ||||||
| <7 days | 8 (36.4) | 15 (28.3) | 3 (42.9) | 20 (29.4) | ||
| >7 days | 7 (31.8) | 19 (35.8) | 1 (14.3) | 25 (36.8) | ||
| Unknown | 7 (31.8) | 19 (35.8) | 0.789 | 3 (42.9) | 23 (33.8) | 0.485 |
| HOSPITAL STAY PRIOR TO BACTEREMIA | ||||||
| <2 days | 7 (31.8) | 14 (26.4) | 2 (28.6) | 19 (27.9) | ||
| Between 2 and 7 days | 2 (9.1) | 2 (3.8) | 1 (14.3) | 3 (4.4) | ||
| >7 days | 13 (59.1) | 35 (66) | 4 (57.1) | 44 (64.7) | ||
| Unknown | 0 (0) | 2 (3.8) | 0.586 | 0 (0) | 2 (2.9) | 0.700 |
| RECURRENT ADMISSION | ||||||
| Yes | 2 (9.1) | 6 (11.3) | 0 (0) | 8 (11.8) | ||
| No | 20 (90.9) | 47 (88.7) | 0.776 | 7 (100) | 60 (88.2) | 0.337 |
| FOCUS OF INFECTION | ||||||
| No/Unknown | 3 (13.6) | 14 (26.4) | 1 (14.3) | 16 (23.5) | ||
| Pneumonia | 1 (4.5) | 2 (3.8) | 1 (14.3) | 2 (2.9) | ||
| Gastroenteritis | 0 (0) | 3 (5.7) | 0 (0) | 3 (4.4) | ||
| UTI | 6 (27.3) | 7 (13.2) | 2 (28.6) | 11 (16.2) | ||
| SStI | 8 (36.4) | 22 (41.5) | 2 (28.6) | 28 (41.2) | ||
| Central line associated | 1 (4.5) | 1 (1.9) | 0 (0) | 2 (2.9) | ||
| Portal catheter associated | 3 (13.6) | 4 (7.5) | 0.507 | 1 (14.3) | 6 (8.8) | 0.702 |
| PLACEMENT OF CVC | ||||||
| Yes | 7 (31.8) | 16 (30.2) | 2 (28.6) | 21 (30.9) | ||
| <10 days | 6 (27.3) | 12 (22.6) | 3 (42.9) | 15 (22.1) | ||
| >10 days | 9 (40.9) | 25 (47.2) | 2 (28.6) | 32 (47.1) | ||
| No | 7 (31.8) | 16 (30.2) | 0.866 | 2 (28.6) | 21 (30.9) | 0.442 |
| OUTCOME | ||||||
| Death | 5 (22.7) | 2 (3.8) | 4 (57.1) | 3 (4.4) | ||
| Recovery | 17 (77.3) | 51 (96.2) | 0.010 | 3 (42.9) | 65 (95.6) | <0.0001 |
| Sepsis | 5 (22.7) | 3 (5.7) | 0.029 | 4 (57.1) | 4 (5.9) | <0.0001 |
| Intubation | 5 (22.7) | 2 (3.8) | 0.010 | 4 (57.1) | 3 (4.4) | <0.0001 |
| HSCT | 13 (59.1) | 29 (54.7) | 0.728 | 4 (57.1) | 38 (55.9) | 0.949 |
N.B. MASCC, Multinational Association of Supportive Care in Cancer, UTI, Urinary tract infection; SStI, Skin and soft tissue Infection; CVC, Central Venous Catheter; HSCT, Hematopoietic stem cell transplantation.